ARTEMIS Synovial Markers in Arthritis Childhood

The aim of this study is to find markers that could differentiate infectious and inflammatory arthritis. The investigators want to find markers by differential analysis by compare synovial fluids of septic and inflammatory arthritis. The investigators will use for this analysis, proteomics, cytokine dosage and monocyte typing by flow cytometry analysis. The investigators will use one marker or a score with biological and clinical data to discriminate arthritis of infectious and inflammatory etiology.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Septic Arthritis Arthritis Arthritis, Infectious Arthritis, Juvenile Autoimmune Diseases Connective Tissue Diseases Disease Immune System Diseases Infections Joint Diseases Juvenile Idiopathic Arthritis Musculoskeletal Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

6 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hôpital Arnaud de Villeneuve

Montpellier, 34295, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Septic arthritis with bacteriological identification
Juvenile idiopathic arthritis beyond the ILAR definition
Having acute arthritis requiring an articular draining
Child benefiting from a national insurance scheme
Collection of the consent of the parents or the legal representative

Exclusion criteria

Contraindication in an articular draining: platelet 50 000 / mm3, Rate of prothrombins lower than 70 %, activated partial thromboplastin times (APTT)> 1,5
Treatment by biotherapy, corticoids or other immuno suppressor in the month preceding the articular draining.
Treatment by antibiotic begun more than 24 hours before the draining.

Treatment and study plan

Articular punction, salivary samples, blood sample

Procedure

Other names: Proteomic analysis, Cytokine dosage, Monocyte

Primary outcomes

Qualitative analysis of new biological markers (proteic, cytokine or cellular) that discriminate inflammatory and infectious arthritis.

Time frame: 1 day

Identify blood sampling biomarkers of Arthritis childhood

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Acronym: ARTEMIS

Important dates

Study start: 2015
Primary completion: 2018
Study completion: 2018
First posted: Jul 22, 2015
Registry last updated: Dec 31, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed